Psoriasis

Researchers are evaluating the effects of delgocitinib cream 20 mg/g applied twice daily compared to a non-active cream (vehicle) in adults aged 18 years and older with mild to severe palmoplantar pustulosis (PPP). This skin condition involves pustules on the palms and soles and can persist for more than three months. The study aims to determine if delgocitinib improves the severity and symptoms of PPP over 16 weeks. Participants will be randomly assigned to one of two groups: one applying delgocitinib cream twice a day and the other applying a matching vehicle cream twice a day, both for 16 weeks. The study is double-blind, meaning neither participants nor researchers know which treatment is given. The total study duration for each participant is about 18 weeks, including approximately 9 visits. During the study, participants will attend regular visits where their skin condition will be evaluated using several measures, including the Palmoplantar Pustulosis Area and Severity Index (PPPASI) and Physician Global Assessment (PGA). Researchers will also assess symptoms like pustule counts, itch, pain, quality of life, and work productivity. Safety and any side effects will be monitored throughout the study period.

Researchers are evaluating the safety and effectiveness of a drug called D-2570 for adults with moderate to severe plaque psoriasis. This randomized, double-blind, placebo- and active-controlled clinical trial is conducted across multiple centers and includes patients aged 18 to 70 years. The study aims to compare different doses of D-2570 with placebo and another drug, BMS-986165, to understand how well D-2570 works and its safety profile. Participants will receive different doses of D-2570, BMS-986165, or a placebo tablet. The treatment period lasts 16 weeks after enrollment. Throughout the study, both participants and investigators remain unaware of which treatment is given to ensure unbiased results. Blood samples will be collected at scheduled times for pharmacokinetic and pharmacodynamic analysis to monitor how the drug behaves in the body. During the study, participants will attend regular visits for safety and efficacy assessments, including physical exams and laboratory tests such as blood chemistry and urinalysis. The main outcome measured is the treatment's impact on plaque psoriasis over 16 weeks, with safety monitored through an average of 28 weeks until study completion. Participants will also have a safety follow-up after treatment ends to support ongoing monitoring throughout the study duration.

Researchers are evaluating the safety and effectiveness of TQH2929 injection in patients experiencing acute flare-ups of generalized pustular psoriasis, a severe skin condition. This multicenter, randomized, double-blind, placebo-controlled phase II clinical trial aims to enroll 36 participants to compare the investigational drug against a placebo. Participants receive a single intravenous infusion of either TQH2929, a humanized monoclonal antibody that interferes with the disease's signal pathways, or a placebo that contains no active ingredients. The study design includes careful monitoring of treatment effects and side effects, conducted in a blinded manner with both participants and investigators unaware of group assignments. During the study, participants will undergo assessments to measure skin symptoms and disease severity using various scales at one and four weeks after treatment. Researchers will also monitor drug levels, immune responses, and any adverse events over several months. The total participation time includes follow-up visits to ensure safety and evaluate longer-term outcomes.

Researchers are evaluating the long-term safety of subcutaneous guselkumab in children with moderately to severely active ulcerative colitis, Crohn's disease, or juvenile psoriatic arthritis. This study includes pediatric participants who have previously received guselkumab in primary studies and aims to monitor adverse events over an extended period. Participants who completed one of three primary pediatric guselkumab studies may join this long-term extension study if the investigator believes they will benefit from continued therapy. Guselkumab is given as a subcutaneous injection every 8 or 4 weeks, depending on the dosing regimen from the original study. Some participants have an option to adjust dosing frequency once during the extension, while others continue with their original schedule without changes. During the study, participants will have regular safety assessments focusing on treatment-emergent adverse events for up to nearly 7 years. Consent from parents or legal representatives and assent from children able to understand the study are required. Researchers will monitor participants closely, collecting data on safety and tolerability while allowing continued access to guselkumab throughout the extension period.

Researchers are evaluating how well the medicine zasocitinib works, how safe it is, and how children and teenagers aged 4 to under 18 with moderate-to-severe plaque psoriasis respond to it. The study is a Phase 3 trial that includes two parts: Part A with both children and teenagers, and Part B with only children. Initially, only teenagers who meet the study rules can participate, and children may join once enough information from other studies is available. Participants in Part A will be randomly assigned to receive either zasocitinib or a placebo for the first 16 weeks, after which all participants will receive zasocitinib for the remainder of the study. Participants in Part B will receive zasocitinib throughout the study. Dosages are given orally once daily, with doses adjusted by weight for children aged 4 to under 12 years, and a fixed dose for teenagers aged 12 to under 18 years. The study includes a double-blind placebo-controlled period followed by an open-label period. Participants will be involved for up to 4 years and 2 months, including up to 35 days for screening, 208 weeks of treatment, and a 4-week safety follow-up. During this time, participants will visit the study site multiple times for assessments, including skin evaluations, quality of life questionnaires, and blood tests to monitor drug levels and safety. Researchers will measure how many participants achieve clear or almost clear skin, improvements in psoriasis severity scores, quality of life improvements, and monitor the medicine's concentration in the body.

Researchers are investigating personalized precision medicine for adults aged 18 to 75 with psoriasis or psoriatic arthritis. This multi-center randomized clinical trial compares a prescreen strategy-based biologics selection using immune cell biomarkers versus standard guideline-based biologics treatment. The study also explores cardiovascular biomarkers to understand disease impact and treatment effects. Participants are randomly assigned to one of two groups: a strategic group where biologics are selected based on individual immune cell screening and biomarker scores, and a standard group receiving biologics per current guidelines without prescreening. Biologics studied include adalimumab, etanercept, certolizumab pegol, golimumab, ustekinumab, secukinumab, ixekizumab, bimekizumab, and brodalumab. Blood samples are cultured to analyze cytokine responses, with follow-up visits scheduled at multiple intervals up to 72 weeks, extending up to 3 years if needed. Participants undergo clinical assessments including Psoriasis Area and Severity Index (PASI), joint counts, Disease Activity in Psoriatic Arthritis (DAPSA) score, Dermatology Life Quality Index (DLQI), and body surface area affected. Cardiovascular health is monitored by measuring internal carotid artery thickness at 6 months, 1 year, and 2 years. Researchers also collect data on pruritus and cytokine levels to evaluate treatment effects. Safety and efficacy outcomes are assessed regularly throughout the study period, with extended follow-up for up to 5 years.

Researchers are evaluating the safety and effectiveness of different doses of ZL-1102 topical gel in treating adults with chronic plaque psoriasis. This phase 2 study is randomized, double-blind, and vehicle-controlled, involving around 250 participants to compare multiple doses of ZL-1102 against a placebo gel over 16 weeks. Participants will be assigned to one of five groups receiving either ZL-1102 gel at varying doses and frequencies or a matching placebo gel. The treatments include ZL-1102 1% gel applied twice daily, ZL-1102 3% gel applied once or twice daily, or placebo gel applied once or twice daily. The treatment period lasts for 16 weeks, followed by assessments. During the study, participants will undergo regular evaluations including assessments of psoriasis severity using tools like IGA and mPASI scores. Researchers will monitor treatment efficacy, skin tolerability, serum drug levels, and potential side effects through week 20. Participants will be followed closely to measure improvements and adverse events, ensuring comprehensive safety monitoring throughout the study duration.

Researchers are evaluating camoteskimab, a drug being studied in adults with moderate-to-severe atopic dermatitis. This phase 2b study is multicenter, randomized, double-blind, and placebo-controlled, aiming to assess the drug's effects compared to placebo. Participants include those who have not been treated before and those who have had an inadequate response to previous biologic therapies. The study has two parts: Part 1 is a 24-week period where participants are randomly assigned to one of four groups receiving one of three doses of camoteskimab or a placebo, all given by subcutaneous injection. In Part 2, an extension period, all participants will receive camoteskimab. This design allows researchers to compare the drug doses with placebo initially and then provide treatment to all participants. Participants will be involved for at least 24 weeks in the placebo-controlled phase and beyond during the extension. They will undergo assessments including the Eczema Area and Severity Index (EASI), Investigator Global Assessment (IGA), and peak itch ratings. Researchers will measure changes in eczema severity, itch intensity, and skin condition over time. Safety and adherence will be monitored throughout the study period to evaluate the drug's effects and tolerability.

Researchers are evaluating the efficacy and safety of QL2106 injection compared to Tremfya® in patients with moderate to severe plaque psoriasis. This Phase 3, multicenter, randomized, double-blind, parallel, and active-controlled study plans to enroll 318 participants to better understand treatment effects in this population. Participants will be randomly assigned in equal numbers to receive either QL2106 injection or Tremfya®. Both treatments are given by subcutaneous injection at Week 0, Week 4, and then every 8 weeks. The recommended dose for both is 100 mg. This study uses a quadruple blinding method to maintain objectivity. Throughout the study, researchers will assess the proportion of patients achieving a 75% improvement in the Psoriasis Area and Severity Index (PASI-75) at Week 16. Participants will be monitored for safety and treatment response during the trial. The study is expected to continue until February 2028, with participants involved in regular visits according to the treatment schedule for assessment and care.

Researchers are evaluating the safety and effectiveness of MC2-01 cream for treating plaque psoriasis in Chinese adults aged 18 years and older. This phase 3, multi-center, randomized, and investigator-blinded study compares MC2-01 cream to CAL/BDP gel and a vehicle cream in participants with stable plaque psoriasis affecting the body and/or scalp. The study includes a screening period, treatment period, and safety follow-up to assess outcomes carefully. Participants will apply one of the study treatments—MC2-01 cream, MC2-01 vehicle cream, or CAL/BDP gel—once daily for 8 weeks. Each treatment contains calcipotriene and betamethasone dipropionate in specified concentrations, except the vehicle cream which does not contain active ingredients. The study treatment is delivered topically to areas affected by plaque psoriasis, primarily on the trunk, limbs, and scalp. Throughout the study, participants will attend visits to evaluate their psoriasis using tools like the Physician's Global Assessment (PGA) and modified Psoriasis Area and Severity Index (mPASI). Other assessments include safety monitoring through skin reactions, vital signs, and ECGs. Researchers will also gather information on treatment convenience and perform follow-up safety checks after treatment ends. Total involvement includes screening, 8 weeks of treatment, and additional safety follow-up to monitor participant well-being.